The leading cause of congestive heart failure (CHF) is post-myocardial infarction (MI) cardiomyopathy, which results from pathologic remodeling of viable heart muscle after loss of infarcted tissue. Some pharmacologic interventions slow declines in cardiac function, but there remain no means to halt the progression of post-MI remodeling to end-stage failure. Molecular and cellular interventions in cardiac function are therefore viewed as an important new horizon. Cardiac hypertrophy can be physiologic, a stable and reversible process observed in exercise and pregnancy, or pathologic, an irreversible response to stresses such as hypertension and MI that degenerates to dilated cardiomyopathy. Many molecular pathways are known to be active during pathologic and, to a lesser degree, physiologic hypertrophy, but it is not clear how these distinct responses are regulated, nor how differing stresses are translated into different outcomes. During the course of the current R01, we discovered that loss of alpha adrenergic receptors, an important source of physiologic hypertrophic signaling, leads to an increase, rather than a decrease, in post-MI hypertrophy. This increase, however, was characterized by pathologic hypertrophy, suggesting a dynamic balance between physiologic and pathologic hypertrophy, even in response to pathologic stresses. If a loss of the former can increase the latter, therapeutic instigation of a heightened level of physiologic hypertrophy may lessen the induction of pathologic hypertrophy. In the proposed studies, we will test this translational hypothesis utilizing a new and unique genetic model of regulatable MEK1-ERK1/2 signaling. Our first Specific Aim will involve induction of physiologic hypertrophic MEK1-ERK1/2 signaling at critical time points after MI to assess a resulting shift away from pathologic hypertrophy during post-MI remodeling.
The second Aim will focus on a careful dissection of the downstream molecular effectors of this change, and elucidate specific pathways by which the myocardium is shifted toward physiologic or pathologic hypertrophy. In the third Specific Aim, we will evaluate whether these observations are specific to post-MI pathophysiology or whether they represent a generalizable, novel understanding of cardiac hypertrophy by applying the most successful strategy and analyses from Aims 1 and 2 to an alternative form of pathologic hypertrophy observed after experimental aortic constriction. Finally, our new model of regulatable MEK1-ERK1/2 upregulation will allow us to combine the induction of physiologic hypertrophy with surgical ventricular reconstruction, a necessary adjunct to any molecular therapy applied to severely misshapen hearts in the later stages of cardiomyopathy.

Public Health Relevance

Cardiovascular disease remains the greatest cause of morbidity and mortality in the developed world, and heart failure represents a growing international epidemic. Left ventricular hypertrophy is a compensatory response to stress which can preserve or enhance cardiac function. Whereas physiologic hypertrophy, as seen with exercise, is stable and reversible, pathologic hypertrophy, seen in various disease states, is irreversible and leads to deterioration of cardiac structure and function. This study will elucidat the molecular signaling differences that can push a heart toward either physiological or pathological hypertrophy. It will also build upon recent observations from our laboratory that suggest that therapeutic induction of physiologic signaling can reduce the degree of pathologic changes seen in certain disease states. This strategy may provide an important new therapeutic approach for treating cardiac diseases.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Bioengineering, Technology and Surgical Sciences Study Section (BTSS)
Program Officer
Evans, Frank
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Schools of Medicine
San Francisco
United States
Zip Code
Yeh, Che-Chung; Fan, Yanying; Yang, Yi-Lin et al. (2017) Atrial ERK1/2 activation in the embryo leads to incomplete Septal closure: a novel mouse model of atrial Septal defect. J Biomed Sci 24:89
Fan, Yanying; Yang, Yi-Lin; Yeh, Che-Chung et al. (2017) Spacial and Temporal Patterns of Gene Expression After Cardiac MEK1 Gene Transfer Improve Post-Infarction Remodeling Without Inducing Global Hypertrophy. J Cell Biochem 118:775-784
Yeh, Che-Chung; Malhotra, Deepak; Yang, Yi-Lin et al. (2013) MEK1-induced physiological hypertrophy inhibits chronic post-myocardial infarction remodeling in mice. J Cell Biochem 114:47-55
Yeh, Che-Chung; Li, Hongzhe; Malhotra, Deepak et al. (2010) Distinctive ERK and p38 signaling in remote and infarcted myocardium during post-MI remodeling in the mouse. J Cell Biochem 109:1185-91
Wall, Samuel T; Yeh, Che-Chung; Tu, Richard Y K et al. (2010) Biomimetic matrices for myocardial stabilization and stem cell transplantation. J Biomed Mater Res A 95:1055-66
Yeh, Che-Chung; Malhotra, Deepak; Li, Hongzhe et al. (2009) Surgical ventricular reconstruction in mice: elucidating potential targets for combined molecular/surgical intervention. J Thorac Cardiovasc Surg 137:942-9
Li, Hongzhe; Malhotra, Deepak; Yeh, Che-chung et al. (2009) Myocardial survival signaling in response to stem cell transplantation. J Am Coll Surg 208:607-13
Yeh, Che-Chung; Li, Hongzhe; Malhotra, Deepak et al. (2009) Sphingolipid signaling and treatment during remodeling of the uninfarcted ventricular wall after myocardial infarction. Am J Physiol Heart Circ Physiol 296:H1193-9